Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions.Strategic Alliance and Option • May 15th, 2017 • Editas Medicine, Inc. • Biological products, (no disgnostic substances) • New York
Contract Type FiledMay 15th, 2017 Company Industry JurisdictionThis STRATEGIC ALLIANCE AND OPTION AGREEMENT (the “Agreement”) is entered into and made effective as of March 14, 2017 (the “Effective Date”) by and between Editas Medicine, Inc., a Delaware corporation (“Editas”) and Allergan Pharmaceuticals International Limited, a public company limited by shares organized under the laws of Ireland (“Allergan”). Editas and Allergan are each referred to herein by name or as a “Party” or, collectively, as “Parties.”